A patient with lax, fragile skin receives intravenous medication that was inadvertently administered subcutaneously by a new nurse; what complications can occur and what is the appropriate immediate management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Immediate Management of Inadvertent Subcutaneous Administration of IV Medications

Stop the infusion immediately, leave the cannula in place, attempt gentle aspiration of the extravasated solution, assess the specific medication administered to determine vesicant properties, and initiate drug-specific antidote therapy if indicated while closely monitoring for tissue necrosis.

Potential Complications

The severity of tissue injury depends critically on the properties of the extravasated medication 1, 2:

High-Risk Medications (Vesicants)

  • Chemotherapy agents (anthracyclines, vinca alkaloids, mitomycin C): Can cause severe tissue necrosis, ulceration, and permanent scarring
  • Vasopressors (dopamine, norepinephrine, epinephrine): Cause vasoconstriction leading to tissue ischemia and necrosis
  • Hyperosmolar solutions (calcium, potassium chloride >40 mEq/L, parenteral nutrition, contrast media): Osmotic tissue damage
  • Extreme pH solutions (phenytoin, promethazine): Chemical burns from acidic or basic properties

Expected Tissue Damage Progression

  • Only one-third of extravasations progress to ulceration 1
  • Complications range from mild erythema and swelling to full-thickness skin necrosis requiring surgical debridement 2, 3
  • Long-term sequelae include complex regional pain syndrome, functional limitation, large scars, or rarely amputation 4

Immediate Management Algorithm

Step 1: Stop and Assess (First 5 Minutes)

  1. Stop the infusion immediately but leave the cannula in place 1, 5
  2. Attempt gentle aspiration through the existing line to remove as much extravasated solution as possible 1
  3. Avoid manual pressure over the extravasated area 1
  4. Identify the specific drug and volume extravasated 1

Step 2: Drug-Specific Antidote Administration (Within 6 Hours)

For Anthracyclines (doxorubicin, daunorubicin, epirubicin):

  • Administer IV dexrazoxane 1000 mg/m² on days 1-2, then 500 mg/m² on day 3, starting within 6 hours 1
  • Give in a large vein away from extravasation site (opposite arm)
  • Remove ice packs 15 minutes before dexrazoxane administration
  • Do NOT apply DMSO with dexrazoxane 1
  • Dose reduction to 50% if creatinine clearance <40 mL/min 1

For Vinca Alkaloids (vincristine, vinblastine):

  • Inject hyaluronidase 1-6 mL of 150 U/mL solution through the existing IV line 1
  • Usual dose: 1 mL hyaluronidase per 1 mL of extravasated drug 1

For Vasopressors (dopamine, norepinephrine):

  • Administer intradermal phentolamine as the antidote of choice 6
  • Alternative: topical vasodilators or intradermal terbutaline 6

For Hyperosmolar Solutions (calcium, TPN):

  • Consider hyaluronidase depending on severity and risk of tissue injury 6

For Mechlorethamine:

  • Immediate subcutaneous sodium thiosulfate 2 mL of 1/6 molar solution (mix 4 mL of 10% sodium thiosulfate with 6 mL sterile water); inject 2 mL per mg of extravasated drug 1

For Anthracyclines, Mitomycin C, or Platinum Salts (if dexrazoxane unavailable):

  • Apply topical DMSO 99% at 4 drops per 10 cm² of affected skin surface 1
  • Repeat every 8 hours for 1 week
  • Apply within first 10 minutes for best results 1
  • Let air dry without dressing 1

Step 3: Non-Pharmacological Measures

For Most Extravasations:

  • Apply dry cold compresses for 20 minutes, 4 times daily for 1-2 days 1
  • Elevate the affected limb 1
  • Avoid alcohol compresses 1

Exception - For Vinca Alkaloids:

  • Apply warm compresses instead of cold 1

Step 4: Pain Management

  • Administer analgesia as needed 5
  • Non-pharmacological pain relief measures 5

Step 5: Monitoring and Documentation

Immediate Assessment:

  • Grade severity using an infiltration scale (e.g., Pediatric Peripheral Intravenous Infiltration Assessment Tool) 5
  • Document: patient identification, date/time, drug name and diluent, signs/symptoms, IV access description, extravasation area and volume, management steps 1
  • Photographic documentation for follow-up and decision-making 1

Ongoing Monitoring:

  • Grade 1-2 injuries: Observe hourly for 12 hours 5
  • Grade 3-4 injuries: Notify physician immediately 5
  • Monitor for progression to necrosis over 10 days 1

Step 6: Escalation to Surgical Management

Indications for Surgical Consultation:

  • Unresolved tissue necrosis after 10 days 1
  • Persistent pain lasting >10 days 1
  • Full-thickness skin necrosis 3
  • Chronic ulcer formation 3

Surgical Options:

  • Wide three-dimensional debridement with biologic dressing and delayed split-thickness skin graft (2-3 days) 1
  • Fasciocutaneous flaps for larger defects 2
  • Subcutaneous wash-out procedure (within 345 minutes) only in experienced surgical units 1

Critical Pitfalls to Avoid

  1. Do NOT apply manual pressure to the extravasation site - this worsens tissue damage 1
  2. Do NOT remove the cannula before attempting aspiration 1
  3. Do NOT use subcutaneous corticosteroids - they are ineffective 1
  4. Do NOT combine DMSO with dexrazoxane for anthracyclines 1
  5. Do NOT delay antidote administration - efficacy decreases significantly after 6 hours for dexrazoxane 1
  6. Do NOT use cold compresses for vinca alkaloids - use warm instead 1

Patient Communication and Reporting

  • Inform the patient immediately about the extravasation and expected course 1
  • Update parents/family on progress regularly 5
  • Complete incident reporting for quality improvement and legal documentation 1, 5
  • Discuss potential time to resolution and legal implications if vesicant drug involved 1

Special Consideration: Patients with Lax Skin

Elderly patients with fragile, lax skin are at higher risk for unrecognized extravasation because tissue compliance may mask early swelling. The subcutaneous space can accommodate larger volumes before visible signs appear, potentially delaying recognition and increasing tissue damage. This emphasizes the critical importance of immediate recognition and intervention in this vulnerable population.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.